ArticlePharmaceutical research2008
Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems.
Article in Pharmaceutical research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 215 citations in OpenAlex.
- A Quantitative Review and Meta-models of the Variability and Factors Affecting Oral Drug Absorption-Part II: Gastrointestinal Transit Time.The AAPS journal · 2016Pooled it
- Meal-induced acceleration of tablet transit through the human small intestine.Pharmaceutical research · 2009Trial
- Formulation approaches for colon-specific drug delivery: conventional to nanocarrier systems.RSC advances · 2026Review
- Development of a pH Gradient Dissolution Condition to Predict the Behavior of Delayed Release Formulations under Fed In Vivo Condition.AAPS PharmSciTech · 2025Article
- Delivery of Probiotic-Loaded Microcapsules in the Gastrointestinal Tract: A Review.Probiotics and antimicrobial proteins · 2025Review
- Advances in colon-targeted drug technologies.Current opinion in gastroenterology · 2025Review
- Nutriose, a Dextrin-based Natural Polysaccharide Polymer with Beneficial Activities as a Candidate for Future Drug Delivery: A Review.Combinatorial chemistry & high throughput screening · 2025Review
- Dual-Stage Targeted Oral Drug Loaded Nanostructured Lipid Carriers Enhance the Efficacy of Ulcerative Colitis.International journal of nanomedicine · 2025Article
- Recognizing the biological barriers and pathophysiological characteristics of the gastrointestinal tract for the design and application of nanotherapeutics.Drug delivery · 2024Review
- Response ofMicroorganisms · 2024Review
- Colon targeting in rats, dogs and IBD patients with species-independent film coatings.International journal of pharmaceutics: X · 2024Article
- Fitness trade-offs of multidrug efflux pumps inApplied and environmental microbiology · 2024Article
- Insights on NefeconDrug design, development and therapy · 2024Review
- Gastrointestinal Transit Times in Health as Determined Using Ingestible Capsule Systems: A Systematic Review.Journal of clinical medicine · 2023Review
- Predictive Potential of BCS and Pharmacokinetic Parameters on Study Outcome: Analysis of 198 In Vivo Bioequivalence Studies.European journal of drug metabolism and pharmacokinetics · 2023Article
- Perspectives of colon-specific drug delivery in the management of morning symptoms of rheumatoid arthritis.Inflammopharmacology · 2023Review
- Impact of gastric and bowel surgery on gastrointestinal drug delivery.Drug delivery and translational research · 2023Review
- Heterogeneity and Evolutionary Tunability of Escherichia coli Resistance against Extreme Acid Stress.Microbiology spectrum · 2022Article
- In Vitro Methodologies for Evaluating Colon-Targeted Pharmaceutical Products and Industry Perspectives for Their Applications.Pharmaceutics · 2022Review
- Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment.International journal of nanomedicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOral pH triggered drug delivery systems, for targeting to the lower gastrointestinal tract, show erratic behaviour in vivo. This study aimed to establish correlations between in situ gastrointestinal pH, transit time or feed status and the disintegration of pH-responsive dosage forms designed to dissolve above pH 7.
methodsTablets (radiolabelled with Technetium 99m) coated with Eudragit S were administered to eight healthy subjects in a three-way crossover study after an overnight fast. Food was administered either 30 min after (pre-feed) or 4 h after (fasted) tablet ingestion. Concurrently, a Bravo pH monitoring capsule (radiolabelled with Indium 111) was administered in a "freefall manner". In a third arm of the study tablets were given immediately after breakfast (fed). Transit was followed by gamma scintigraphy.
resultsGastrointestinal pH showed variability between and within individuals but no differences were seen between pre-feed and fasted states. Three tablets failed to disintegrate in pre-feed and fed regimens and one in the fasted state; this has been tentatively linked to ileocaecal pH and ileoceacal junction residence time.
conclusionsIn vivo performance of "pH-responsive" dosage forms is complex and influenced by a multitude of factors other than just in situ pH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.